SCHEMBL1010432

SCHEMBL1010432

COc1cncc(NC(=O)Oc2ccccc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.49
GAA P10253 4/20 0.49
HTT P42858 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
MAPT P10636 4/20 0.46
POLB P06746 1/20 0.44
BRAF P15056 1/20 0.43
CCNE1 P24864 1/20 0.43
CDK2 P24941 1/20 0.43
CDK5 Q00535 1/20 0.43
KDM4E B2RXH2 4/20 0.43
THRB P10828 1/20 0.43
GFER P55789 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
NPSR1 Q6W5P4 2/20 0.42
RAB9A P51151 1/20 0.42
HSD17B10 Q99714 1/20 0.42
LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27785460 0.86 BRAF (0.42) ALDH1A1GAAHTTSMN1; SMN2MEN1
SCHEMBL16775796 0.85 MAPK8 (0.46) ALDH1A1MEN1KMT2AMAPTPOLB
SCHEMBL1011190 0.84 CDK2 (0.51) ALDH1A1GAAHTTSMN1; SMN2MEN1
SCHEMBL59779 0.83 ALDH1A1 (0.51) ALDH1A1GAAHTTSMN1; SMN2MEN1
SCHEMBL9520682 0.81 ALDH1A1 (0.52) ALDH1A1GAAHTTSMN1; SMN2MEN1
SCHEMBL31028805 0.79 ALDH1A1 (0.50) ALDH1A1GAAHTTSMN1; SMN2MEN1
SCHEMBL1011423 0.79 ALDH1A1 (0.50) ALDH1A1GAAHTTSMN1; SMN2MEN1
SCHEMBL6517886 0.79 KDM4E (0.42) ALDH1A1BRAFKDM4ECYP1A2GRM5
SCHEMBL896513 0.78 ALDH1A1 (0.53) ALDH1A1GAAHTTSMN1; SMN2MEN1
SCHEMBL1576702 0.78 MAPT (0.59) ALDH1A1GAAHTTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044052-B2 Inhibitors of fatty acid amide hydrolase; N-pyridin-3-yl-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide; elevate brain anandamide levels; pain, urinary incontinence, cognitive disorders, anxiety, depression, sleeping, eating, movement disorders, glaucoma, psoriasis PFIZER INC. (US) 2011-10-25 US disclosed
EP-2076508-B1 BIARYL ETHER UREA COMPOUNDS PFIZER PROD INC (US) 2011-01-05 EP disclosed
EP-2076508-A2 BIARYL ETHER UREA COMPOUNDS Pfizer Products Inc. (US) 2009-07-08 EP disclosed
US-20080261941-A1 Biaryl Ether Urea Compounds Jazz Pharmaceuticals Therapeutics, Inc. 2008-10-23 US disclosed
WO-2008047229-A2 BIARYL ETHER UREA COMPOUNDS PFIZER PRODUCTS INC. (US) 2008-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261941-A1 Biaryl Ether Urea Compounds FAAH, FAAH2, LIPC ALDH1A1 360/4885GAA 402/4885HTT 2531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.